《大行》高盛微降国药(01099.HK)目标价至21.17元首季业绩疲弱

阿斯达克财经05-02

高盛发表研报指，国药(01099.HK) 今年首季业绩表现疲弱，主要是受到去年较高基数，以及行业监管措施的影响，期内销售额按年增长1.2%，逊于高盛预测的增长7%。报告指，受季节性因素影响，首季国药毛利率低于7%，销售额及毛利率拖累期内盈利表现，但管理层仍维持全年销售额增幅高于行业约两至三个百分点的指引不变，即预期余下几个季度增长情况将改善。因应最新业绩表现，高盛将国药2024至2026年纯利预测...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2432864074?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180202161553962_s.jpg","is_english":false,"pubTime":"2024-05-02 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432864074","market":"hk","top_or_hot":-1,"title":"《大行》高盛微降国药(01099.HK)目标价至21.17元  首季业绩疲弱","media":"阿斯达克财经","content":"<div>\n<p>高盛发表研报指，国药(01099.HK) 今年首季业绩表现疲弱，主要是受到去年较高基数，以及行业监管措施的影响，期内销售额按年增长1.2%，逊于高盛预测的增长7%。报告指，受季节性因素影响，首季国药毛利率低于7%，销售额及毛利率拖累期内盈利表现，但管理层仍维持全年销售额增幅高于行业约两至三个百分点的指引不变，即预期余下几个季度增长情况将改善。因应最新业绩表现，高盛将国药2024至2026年纯利预测...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346988/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》高盛微降国药(01099.HK)目标价至21.17元  首季业绩疲弱</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》高盛微降国药(01099.HK)目标价至21.17元  首季业绩疲弱\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 15:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346988/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表研报指，国药(01099.HK) 今年首季业绩表现疲弱，主要是受到去年较高基数，以及行业监管措施的影响，期内销售额按年增长1.2%，逊于高盛预测的增长7%。报告指，受季节性因素影响，首季国药毛利率低于7%，销售额及毛利率拖累期内盈利表现，但管理层仍维持全年销售额增幅高于行业约两至三个百分点的指引不变，即预期余下几个季度增长情况将改善。因应最新业绩表现，高盛将国药2024至2026年纯利预测...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346988/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346988/latest-news/AAFN","article_id":"2432864074","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180202161553962_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432864074","pubTimestamp":1714635240,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"高盛发表研报指，国药(01099.HK) 今年首季业绩表现疲弱，主要是受到去年较高基数，以及行业监管措施的影响，期内销售额按年增长1.2%，逊于高盛预测的增长7%。报告指，受季节性因素影响，首季国药毛利率低于7%，销售额及毛利率拖累期内盈利表现，但管理层仍维持全年销售额增幅高于行业约两至三个百分点的指引不变，即预期余下几个季度增长情况将改善。因应最新业绩表现，高盛将国药2024至2026年纯利预测分别下调3.1%、3.4%及4.7%，维持“中性”评级，并下调目标价至21.17元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-02 12:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01099":"国药控股"},"translate_title":"\"Daxing\" Goldman Sachs slightly lowered the target price of Sinopharm (01099. HK) to 21.17 yuan, and the performance in the first quarter was weak","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"高盛发表研报指，国药(01099.HK) 今年首季业绩表现疲弱，主要是受到去年较高基数，以及行业监管措施的影响，期内销售额按年增长1.2%，逊于高盛预测的增长7%。报告指，受季节性因素影响，首季国药毛利率低于7%，销售额及毛利率拖累期内盈利表现，但管理层仍维持全年销售额增幅高于行业约两至三个百分点的指引不变，即预期余下几个季度增长情况将改善。因应最新业绩表现，高盛将国药2024至2026年纯利预测分别下调3.1%、3.4%及4.7%，维持“中性”评级，并下调目标价至21.17元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-02 12:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432864074"}

《大行》高盛微降国药(01099.HK)目标价至21.17元 首季业绩疲弱

精彩评论

《大行》高盛微降国药(01099.HK)目标价至21.17元首季业绩疲弱